Medtronic Inc. enrolled the first of about 2,000 patients in a clinical trial of its Attain line of defibrillator leads, catheters and guidewires.
The Minneapolis-based medical device monolith said the study will ultimately involve subjects at 150 medical centers in 18 countries, examining implant success and complication rates up to three months out. Results are expected some time in 2012.
Enrollees will have received a Medtronic cardiac resynchronization therapy-defibrillator, implanted using devices from the Attain line including the StarFix and Ability left-heart leads; the Command, Select, Deflectable and Prevail catheters; or any Attain delivery catheter, left-heart leads or guidewires. Fifteen new Attain devices have been commerically released over the past two years, according to a press release.